NCT05506683

Brief Summary

Globally, leading causes of death among children one month to 5 years old are pneumonia, diarrheal disease and malaria which are treatable early in the disease-course with low-cost medications. However, these diseases can progress to emergencies when access to care is delayed. In response, a telemedicine and medication delivery service (TMDS) was designed to improve nighttime access to pediatric care and treatment. The TMDS will be implemented in three distinct Ghanaian community to evaluate the clinical safety, operational feasibility of implementing,and scalability of the service.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,239

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 17, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 18, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

November 16, 2022

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

September 25, 2025

Status Verified

September 1, 2024

Enrollment Period

2.6 years

First QC Date

August 17, 2022

Last Update Submit

September 19, 2025

Conditions

Keywords

TelemedicineHealthcare AccessNighttime

Outcome Measures

Primary Outcomes (1)

  • The rate of guideline adherence at the call center.

    Establish the rates of provider adherence to the TMDS clinical guidelines while performing assessments and generating treatment plans at the call center. Points of non-adherence will include severity assessments, missed danger signs and non-indicated or missed antibiotic prescriptions.

    1 day

Secondary Outcomes (3)

  • The rate of guideline adherence at the household.

    1 day

  • Sensitivity, specificity and congruence of clinical variables

    1 day

  • Participant clinical status at 8-12 days

    Between 8-12 days

Other Outcomes (2)

  • Operational metrics: Duration of initial call and time to arrival at household

    1 hour

  • Evaluate qualitative feedback from MotoMeds users

    Between 8-12 days

Study Arms (1)

MotoMeds users (parent/chid participant pairs)

EXPERIMENTAL
Other: MotoMeds pediatric telemedicine and medication delivery service (TMDS)

Interventions

The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.

MotoMeds users (parent/chid participant pairs)

Eligibility Criteria

AgeUp to 10 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Child ≤ 10 years
  • Has an acute medical problem
  • Provides written assent (if 10 years and receives a household visit)

You may not qualify if:

  • Child \> 10 years
  • Child does not have an acute medical problem
  • Medical problem involves physical trauma or mental health
  • Refusal of written assent (if 10 years and receives a household visit)
  • Calls MotoMeds during operating hours
  • Adult (18 years or older)
  • Provides written consent (household visit) or a waiver of documentation of consent (no household visit)
  • Age \< 18 years
  • No written consent or waiver of documentation of consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Ambulance Service

Accra, Accra Metropolitan District, GA-143-8975, Ghana

Location

Related Publications (3)

  • Flaherty KE, Klarman MB, Cajusma Y, Schon J, Exantus L, Beau de Rochars VM, Baril C, Becker TK, Nelson EJ. A Nighttime Telemedicine and Medication Delivery Service to Avert Pediatric Emergencies in Haiti: An Exploratory Cost-Effectiveness Analysis. Am J Trop Med Hyg. 2022 Feb 21;106(4):1063-1071. doi: 10.4269/ajtmh.21-1068. Print 2022 Apr 6.

    PMID: 35189597BACKGROUND
  • Flaherty KE, Zakariah AN, Vescio VA, Osei-Ampofo M, Mahama MN, Agongo V, Becker TK. The state of emergency medical technician education in Ghana. Afr J Emerg Med. 2020 Sep;10(3):107-110. doi: 10.1016/j.afjem.2020.01.009. Epub 2020 Mar 7.

    PMID: 32923318BACKGROUND
  • Flaherty KE, Mahama MN, Klarman MB, Anane-Binfoh NA, Patel MD, Smith NJ, Osei-Ampofo M, Mathelier M, Nelson EJ, Zakariah AN, Afaa TJ, Becker TK. Applying the ADAPT guidance to implement a telemedicine and medication delivery service in a malaria-endemic setting: A prospective cohort study. Trop Med Int Health. 2025 Mar;30(3):181-192. doi: 10.1111/tmi.14081. Epub 2025 Jan 16.

Related Links

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-LymphomaAcute Disease

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Torben K Becker, MD, PhD

    University of Florida

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 17, 2022

First Posted

August 18, 2022

Study Start

November 16, 2022

Primary Completion

July 1, 2025

Study Completion

July 1, 2025

Last Updated

September 25, 2025

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will share

The de-identified individual participant data (IDP) will be made publicly available through a data depository such as Dryad.

Time Frame
The de-identified IDP will likely be made available within 1 year of the conclusion of the study and will remain available indefinitely.
Access Criteria
The de-identified IDP will be publicly available.

Locations